Dr. Hanlee Ji graduated in 1994 from John Hopkins School of Medicine in Internal Medicine and went on to specialize in Oncology. He is currently the Assistant Professor, Medicine – Oncology at Stanford University CA. His research group is pursuing projects focused on personalized medicine. Specifically, he is interested in using genetic and genomic approaches in oncology to improve targeted cancer therapy, make accurate prognosis, predict cancer therapy efficacy and identify clinically relevant cancer mutations.
Frequently, markers identified from NGS profiled tumors are translated into ddPCR assays which enable precision monitoring of a patient over the course of disease and even after health has been restored. This session will illustrate with a number of clinical use cases how dPCR (as demonstrated by ddPCR) is a fit-for-purpose technology approach for serial monitoring of multiple markers in cancer patients. This includes a diversity of marker types such as SNV’s and indels (both driver and passenger), and gene fusions from both truncal rearrangements and drivers of tumorigenesis.